FDA Approves Teva’s Weltruza for Adult Schizophrenia

The US Food and Drug Administration has approved Teva’s Weltruza (olanzapine) for extended-release injectable suspension for the treatment of schizophrenia in adults, according to Thepharmaletter. Teva Pharmaceutical Industries’ US subsidiary disclosed the FDA action.

Thepharmaletter described Weltruza as a new, once-monthly, subcutaneous long-acting injectable, also known as an LAI. The reported approval covers the product’s use in adults with schizophrenia.

FDA action for Weltruza

The FDA approval concerns Weltruza, an olanzapine product for extended-release injectable suspension. Thepharmaletter reported that the product is administered subcutaneously and is designed as a once-monthly LAI.

The regulatory decision is a US milestone for Teva’s Weltruza in the reported schizophrenia indication. The approval details identified by Thepharmaletter include the product name, active ingredient, formulation, route of administration, dosing interval and adult patient population.

Reported product details

• Company: Teva Pharmaceutical Industries’ US subsidiary
• Product: Weltruza
• Active ingredient: Olanzapine
• Regulatory action: FDA approval
• Indication: Schizophrenia in adults
• Formulation: Extended-release injectable suspension
• Administration: Once-monthly subcutaneous long-acting injectable

For pharmaceutical and biotech sales professionals following schizophrenia treatment developments, the event centers on the FDA approval reported by Thepharmaletter. The publisher characterized Weltruza as a new once-monthly subcutaneous LAI and identified Teva’s US subsidiary as the party that revealed the decision.

What the announcement establishes

According to Thepharmaletter, Weltruza is approved for the treatment of schizophrenia in adults. The report identifies the medicine as an olanzapine extended-release injectable suspension, with once-monthly subcutaneous administration.

The announcement provides a defined set of product facts tied to the FDA decision: Teva’s Weltruza, olanzapine, extended-release injectable suspension, a subcutaneous route, a once-monthly interval and the adult schizophrenia indication. Thepharmaletter reported these elements in its coverage of the approval.